Jay Nelson, director of the OHSU Vaccine & Gene Therapy Institute, has been awarded a $10 million contract from the National Institutes of Health for discovery work on new ways to improve vaccines. They were one of seven groups awarded such contracts. Vaccine adjuvants are compounds that bolster the innate immune response, essentially super-charging the vaccine. While adjuvants show great promise in improving vaccines and fighting disease, currently just three are in use–scientists at VGTI and other institutions will begin to screen millions of molecules in search of more. Read the NIH press release here.
Welcome to the Research News Blog
OHSU Research News is your portal to information about all things research at OHSU. Find updates on events, discoveries, and important funding information.
Recent Blog Posts
- OHSU researchers raise concerns with applying the ProtecT Trial data to minority populations
- ScienceTalk ’18: Learn to communicate science to anyone, March 1–2
- Looking for hepatocellular carcinoma biomarkers: Christie Binder In the Lab
- Casey Williamson on ScienceTalk ’18: Learn to communicate science to anyone, March 1–2
- Denesa Oberbeck on ScienceTalk ’18: Learn to communicate science to anyone, March 1–2
- Tom Cooney on Advanced mapping and spatial reasoning tool for OHSU researchers
Awards Basic research Brown bag Cancer Career development Clinical research Collaboration Community Conference Cores Discoveries eIRB Event events Funding Funding focus funding opportunity Funding opportunity Graduate students Integrity Internal funding IRB notes Junior faculty Lecture Limited submission Neuroscience NIH NIH News OCTRI OHSU faculty OHSU Knight Cancer Institute OHSU researchers ONPRC Postdoctoral fellows Research Research administration Research integrity Research resources Research week Seminar Training Translational research TTBD Visiting speaker Workshop